Compare AU
Compare CURE vs. T3MP
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Jpmorgan Climate Chg Sol Active ETF (Managed Fund) (T3MP). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | T3MP | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 80 | 1 |
Median incremental investment | $624.65 | $567.50 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,339.79 | $545.94 |
Average age group | > 35 | < 26 |
Key Summary
CURE | T3MP | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | T3MP.AX was created on 2022-11-28 by JPMorgan. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Fund is to achieve a return through investing in equity securities of companies with exposure to the theme of climate change solutions. |
Top 3 holdings | AbbVie Inc (2.62 %) Alnylam Pharmaceuticals Inc (2.59 %) Amgen Inc (2.59 %) | Hitachi Ltd (4.82 %) Trane Technologies PLC Class A (4.39 %) Quanta Services Inc (4.26 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Industrials (71.96 %) Utilities (28.04 %) Consumer Discretionary (9.68 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (41.52 %) France (12.60 %) Japan (7.95 %) |
Management fee | 0.45 % | 0.55 % |
Key Summary
CURE | T3MP | |
|---|---|---|
Issuer | Global X | JPMorgan |
Tracking index | S&P Biotechnology Select Industry | MSCI All Country World Index - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.55 % |
Price | $46.70 | $60.66 |
Size | $33.491 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 0.34 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 08/12/2022 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | T3MP | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 80 | 1 |
Median incremental investment | $624.65 | $567.50 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,339.79 | $545.94 |
Average age group | > 35 | < 26 |
Pros and Cons
CURE | T3MP | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | T3MP |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |